Amarin reported 91.05 in PE Price to Earnings for its fiscal quarter ending in June of 2023.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amarin 91.05 88.3 Jun/2023
AstraZeneca 24.63 0.71 Sep/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novartis 19.17 3.24 Sep/2026